ALLR Stock Analysis: Buy, Sell, or Hold?
ALLR - Allarity Therapeutics, Inc. Common Stock
$1.16
0.03 (2.65%)
▲
5d:
+8.41%
30d:
+10.48%
90d:
+7.41%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Get Alerted When ALLR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALLR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ALLR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ALLR is currently trading at $1.16, which is considered fair relative to its 30-day fair value range of $1.01 to $1.23.
Technical Outlook: Technically, ALLR is in a uptrend. The price is approaching resistance at $1.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.25 (+697.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALLR is in a uptrend. The price is approaching resistance at $1.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.25 (+697.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.01 -
$1.23
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 697.4% below Wall St target ($9.25)
Fair Price Analysis
30-Day Fair Range
$1.01 -
$1.23
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.01
Resistance Level
$1.19
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.27
Wall Street Target
$9.25
(+697.4%)
Share & Embed Analysis
Last updated: April 02, 2026 5:25 PM ET
Data refreshes hourly during market hours. Next update: 6:25 PM
Data refreshes hourly during market hours. Next update: 6:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |
